The present invention relates generally to medical interventions conducted through vessels such as the major arteries, and more particularly to access and deployment configurations for conducting percutaneous procedures such as percutaneous valve replacement.
Gaining access to the heart is a continued challenge in cardiovascular medicine. Conventional procedures for accomplishing tasks such as valve replacement generally involve a thoracotomy and/or creation of one or more access ports across the wall of the heart itself, which is relatively highly invasive and therefore undesirable. Recent progress has been made in the area of percutaneous intervention, wherein instrumentation, such as catheters, guidewires, and prostheses, are brought to the heart through the vessels connected to the heart. One of the challenges with percutaneous approaches to procedures such as valve replacement, is that patients with diseased valves often have diseased major vessels, and the instrumentation required to accomplish a procedure such as a percutaneous valve replacement is often fairly large. For example, the un-expanded delivery size of a CoreValve® aortic valve prosthesis available from Medtronic, Inc. is approximately 18 French; the un-expanded delivery size of a Sapien® valve available from Edwards Lifesciences, Inc. is between 18 and 24 French, depending upon which size is utilized. Such outer sizes do not allow for a conventional guide catheter to be inserted as a protective layer between the tools and the tissue, and therefore the standard of care has become direct insertion of the valve instrumentation through the diseased vessels to reach the target location within or adjacent to the heart. Another complicating factor with such interventions is the fact that it is likely that the aorta through which the devices will be advanced will be diseased (one recent study concluded that 61% of patients over 65 years of age with severe aortic valve stenosis also have severe aortic atherosclerosis; Osranek et al., American Journal of Cardiology, 2009; 103: 713-717).
The subject invention is directed to address such need.
One embodiment is directed to a method for deploying a device to a distal location across a diseased vessel, comprising inserting a railed expandable sheath into a diseased vessel at a point of entry, the sheath defining a lumen there-through and comprising two or more longitudinal rail structures coupled to a sheet-like member, the sheath having a collapsed configuration, wherein the sheath has a first cross-sectional outer diameter defines a first lumen inner diameter, and an expanded configuration, wherein the sheath has a second cross-sectional outer diameter and second lumen inner diameter, such that in the collapsed configuration, the sheath is configured to be advanced across at least a portion of the diseased vessel to a position adjacent the distal location without substantial size interference between the first cross-sectional outer diameter of the sheath and an inner diameter profile of a lumen of the diseased vessel; and upon positioning the collapsed configuration to the desired position relative to the distal location, the sheath may be expanded to the expanded configuration with incremental pushing of a device longitudinally through the lumen such that loads imparted upon the sheath by the device are transferred to the rails and distributed to nearby portions of the diseased vessel in a deconcentrated and nonabrasive manner; inserting the device through the lumen to transform the sheath into the expanded configuration. The method further may comprise deploying an emboli filter into the diseased vessel at a location opposite of the sheath point of entry from the distal location. The method further may comprise deploying one or more emboli filters into the diseased vessel to capture emboli which may exit the diseased vessel to associated tributary vessels. The method further may comprise observing one or more radiopaque markers which may be coupled to one or more locations upon the sheath using fluoroscopy while inserting the railed expandable sheath, the markers being configured to be associated with a designated anatomical structure comprising the diseased vessel. The sheet-like member may comprise one or more porous regions configured to allow blood to flow from a position within the lumen to a position across the sheet-like member and outside of the sheath, and inserting may comprise positioning the one or more porous regions adjacent one or more anatomical structures. The one or more porous regions may be configured to be aligned with tributary vessels that join the diseased vessel. The method further may comprise examining a flow pattern adjacent the sheath and designated anatomical structure using Doppler ultrasonic analysis. The ultrasonic analysis may be conducted using a transcutaneous ultrasound transducer. The ultrasonic analysis may be conducted using an intravascular ultrasound transducer which may be coupled to an elongate probe configured to be placed through the lumen of the sheath. Inserting the device may comprise pressing one or more surfaces of the device against exposed portions of the rail structures of the sheath to move the rail structures away from each other into the expanded configuration as the device is advanced. The method further may comprise inserting a balloon dilatation probe into the lumen to complete the reconfiguration of the railed expandable sheath from the collapsed configuration to the expanded configuration. The railed expandable sheath may be self-expanding from the collapsed configuration to the expanded configuration, and the method further may comprise removing a removable expansion retention member configured to retain the railed expandable sheath in the collapsed configuration. The expansion retention member may comprise a corset and tensile member assembly, and the method further may comprise tensioning the tensile member proximally to release the corset and allow expansion to the expanded configuration. The method further may comprise inserting a guidewire through the diseased vessel and using the guidewire to assist with guiding the sheath by advancing the lumen over the guidewire. One or more portions of the rail structures may comprise a ferromagnetic material, and the method further may comprise passing a magnetic probe through the lumen of the expanded configuration to assist with affirmative collapsing of the sheath back to the collapsed configuration. One or more portions of the rail structures may comprise a ferromagnetic material, and the method further may comprise retaining a magnetic probe through the lumen of the expanded configuration to maintain the collapsed configuration until transformation to the expanded configuration is desired. The method further may comprise retracting the sheath out of the point of entry. Inserting the railed expandable sheath may comprise manually manipulating a proximal portion of the sheath to advance the sheath into the diseased vessel. Inserting the railed expandable sheath may comprise manually advancing an elongate probe that is coupled to the railed expandable sheath relative to the diseased vessel. The sheath may comprise two diametrically opposed rail structures coupled to the sheet-like member. The sheath may comprise three rail structures distributed circumferentially equidistantly. The sheath may comprise four rail structures distributed circumferentially equidistantly. The first lumen inner diameter may be equal to between about 0 mm and about 3 mm. The second lumen inner diameter may be equal to between about 6 mm and about 8 mm. The rail structures may comprise a material selected from the group consisting of: polyethylene, ultra-high-molecular weight polyethylene, polyethylene terephthalate, polyoxymethylene, polytetrafluoroethylene, and co-polymers thereof. The rail structures may comprise Nitinol alloy. The rail structures may be coated with a lubricious coating. The sheet-like member may comprise a material selected from the group consisting of: polyethylene, polytetrafluoroethylene, and co-polymers thereof. The diseased vessel may be an aorta. The device may be an implantable prosthesis. The implantable prosthesis may be a cardiac valve. The distal location may be a location within a heart coupled to the diseased vessel. The sheath may be placed across substantially the full length of the aorta between the point of entry and a heart coupled to the aorta. The sheath may be placed across only a portion of the length of the aorta between the point of entry and a heart coupled to the aorta. The sheath may be placed up to, but not across, the carotid artery takeoffs from the aorta. The point of entry may be in a femoral artery coupled to the aorta, and the first cross-sectional outer diameter may be configured to accommodate insertion through the femoral artery. Expanding the sheath to the expanded configuration may comprise unwinding a built up twisting configuration that has been created to maintain the collapsed configuration.
Referring to
Referring to
Referring to
Referring to
Referring to
Further, the mechanical performance of the collapsible railed sheath may be customized and modified by changing the shapes, materials, and positions/orientations of various portions longitudinally (i.e., relative to the length of the overall catheter structure). Several such configurations are illustrated in
Referring to
Referring to
In both
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
The rail structures may comprise various bio-compatible metals, such as titanium, alloys thereof such as Nitinol superalloy, and/or polymers such as polyethylene, ultra-high-molecular weight polyethylene, polyethylene terephthalate, polyoxymethylene, polytetrafluoroethylene, and co-polymers thereof.
The sheet-like member may comprise a material such as polyethylene, polytetrafluoroethylene, or co-polymers thereof.
In one embodiment, a vacuum device such as a syringe may be operatively coupled to the configuration (for example, coupled to or integrated into a proximal handle that forms a manual interface for inserting a railed sheath catheter), and may have an elongate distal portion that may be inserted into a deployed railed sheath catheter to vacuum away emboli that may be present.
Referring to
Referring to
In another embodiment, the removable obturator jacket covering and restraining the underlying compressed distal portion of the sheath, such as in the assembly of
In summary, as described above, the inventive protective configurations provide a means for conducting an intervention while also protecting the underlying tissue and related anatomy; further, the railed sheath configurations assist with delivery and alignment of tools and/or prostheses which may be related to the vascular intervention.
Referring to the process flow embodiment of
Various exemplary embodiments of the invention are described herein. Reference is made to these examples in a non-limiting sense. They are provided to illustrate more broadly applicable aspects of the invention. Various changes may be made to the invention described and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. Further, as will be appreciated by those with skill in the art that each of the individual variations described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present inventions. All such modifications are intended to be within the scope of claims associated with this disclosure.
Any of the devices described for carrying out the subject diagnostic or interventional procedures may be provided in packaged combination for use in executing such interventions. These supply “kits” may further include instructions for use and be packaged in sterile trays or containers as commonly employed for such purposes.
The invention includes methods that may be performed using the subject devices. The methods may comprise the act of providing such a suitable device. Such provision may be performed by the end user. In other words, the “providing” act merely requires the end user obtain, access, approach, position, set-up, activate, power-up or otherwise act to provide the requisite device in the subject method. Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as in the recited order of events.
Exemplary aspects of the invention, together with details regarding material selection and manufacture have been set forth above. As for other details of the present invention, these may be appreciated in connection with the above-referenced patents and publications as well as generally known or appreciated by those with skill in the art. For example, one with skill in the art will appreciate that one or more lubricious coatings (e.g., hydrophilic polymers such as polyvinylpyrrolidone-based compositions, fluoropolymers such as tetrafluoroethylene, hydrophilic gel or silicones) may be used in connection with various portions of the devices, such as relatively large interfacial surfaces of movably coupled parts, if desired, for example, to facilitate low friction manipulation or advancement of such objects relative to other portions of the instrumentation or nearby tissue structures. The same may hold true with respect to method-based aspects of the invention in terms of additional acts as commonly or logically employed.
In addition, though the invention has been described in reference to several examples optionally incorporating various features, the invention is not to be limited to that which is described or indicated as contemplated with respect to each variation of the invention. Various changes may be made to the invention described and equivalents (whether recited herein or not included for the sake of some brevity) may be substituted without departing from the true spirit and scope of the invention. In addition, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention.
Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in claims associated hereto, the singular forms “a,” “an,” “said,” and “the” include plural referents unless specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as claims associated with this disclosure. It is further noted that such claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
Without the use of such exclusive terminology, the term “comprising” in claims associated with this disclosure shall allow for the inclusion of any additional element—irrespective of whether a given number of elements are enumerated in such claims, or the addition of a feature could be regarded as transforming the nature of an element set forth in such claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.
The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of claim language associated with this disclosure.
The present application is a continuation of U.S. patent application Ser. No. 15/228,380 filed Aug. 4, 2016, which is a continuation of U.S. patent application Ser. No. 13/673,898, filed Nov. 9, 2012, which claims the benefit under 35 U.S.C. § 119 to U.S. Provisional Application Ser. No. 61/558,397, filed Nov. 10, 2011; U.S. Provisional Application Ser. No. 61/558,357, filed Nov. 10, 2011; and U.S. Provisional Application Ser. No. 61/717,575, filed Oct. 23, 2012. The foregoing applications are hereby incorporated by reference into the present application in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4655771 | Wallsten | Apr 1987 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4954126 | Wallsten | Sep 1990 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5064414 | Revane | Nov 1991 | A |
5221261 | Termin et al. | Jun 1993 | A |
5290295 | Querals et al. | Mar 1994 | A |
5415664 | Pinchuk | May 1995 | A |
5527282 | Segal | Jun 1996 | A |
5863366 | Snow | Jan 1999 | A |
5911702 | Romley et al. | Jun 1999 | A |
5941896 | Kerr | Aug 1999 | A |
5997508 | Lunn et al. | Dec 1999 | A |
6090072 | Kratoska et al. | Jul 2000 | A |
6179851 | Barbut et al. | Jan 2001 | B1 |
6692462 | Mackenzie et al. | Feb 2004 | B2 |
6706033 | Martinez et al. | Mar 2004 | B1 |
7014647 | Brady et al. | Mar 2006 | B2 |
7766820 | Core | Aug 2010 | B2 |
8206280 | Evans et al. | Jun 2012 | B2 |
8591539 | Gellman | Nov 2013 | B2 |
9370438 | Ginn | Jun 2016 | B2 |
9545298 | Ginn et al. | Jan 2017 | B2 |
9555214 | Ren et al. | Jan 2017 | B2 |
10179048 | Marchand et al. | Jan 2019 | B2 |
10729544 | Ginn et al. | Aug 2020 | B2 |
10874511 | Ginn et al. | Dec 2020 | B2 |
10959844 | Ginn | Mar 2021 | B2 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010053929 | Vonesh et al. | Dec 2001 | A1 |
20020016564 | Courtney et al. | Feb 2002 | A1 |
20020035394 | Fierens et al. | Mar 2002 | A1 |
20020077596 | Mckenzie et al. | Jun 2002 | A1 |
20020077598 | Yap et al. | Jun 2002 | A1 |
20020099431 | Armstrong et al. | Jul 2002 | A1 |
20020138129 | Armstrong et al. | Sep 2002 | A1 |
20030050658 | Trask et al. | Mar 2003 | A1 |
20030144670 | Pavcnik et al. | Jul 2003 | A1 |
20040153117 | Clubb et al. | Aug 2004 | A1 |
20040215167 | Belson | Oct 2004 | A1 |
20040260331 | D'aquanni et al. | Dec 2004 | A1 |
20050021125 | Stack et al. | Jan 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050149113 | Douk et al. | Jul 2005 | A1 |
20050216053 | Douk et al. | Sep 2005 | A1 |
20060052750 | Lenker et al. | Mar 2006 | A1 |
20060135981 | Lenker et al. | Jun 2006 | A1 |
20060149363 | Kujawski | Jul 2006 | A1 |
20060271093 | Holman et al. | Nov 2006 | A1 |
20060282154 | Oepen et al. | Dec 2006 | A1 |
20070016280 | Yacoby et al. | Jan 2007 | A1 |
20070244501 | Horn et al. | Oct 2007 | A1 |
20080033521 | Jorgensen et al. | Feb 2008 | A1 |
20080167705 | Agnew | Jul 2008 | A1 |
20080188928 | Salahieh et al. | Aug 2008 | A1 |
20080195137 | Alleyne et al. | Aug 2008 | A1 |
20080243068 | Ramzipoor | Oct 2008 | A1 |
20090005675 | Grunwald et al. | Jan 2009 | A1 |
20090024202 | Dave et al. | Jan 2009 | A1 |
20090137900 | Bonner et al. | May 2009 | A1 |
20090182278 | Eversull | Jul 2009 | A1 |
20090182360 | Makower | Jul 2009 | A1 |
20090240202 | Drasler et al. | Sep 2009 | A1 |
20090254169 | Spenser et al. | Oct 2009 | A1 |
20090287182 | Bishop et al. | Nov 2009 | A1 |
20100094392 | Nguyen et al. | Apr 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100174355 | Boyle et al. | Jul 2010 | A1 |
20100217304 | Angel et al. | Aug 2010 | A1 |
20100234932 | Arbefeuille et al. | Sep 2010 | A1 |
20100268264 | Bonnette et al. | Oct 2010 | A1 |
20100305604 | Pah | Dec 2010 | A1 |
20100312268 | Belson | Dec 2010 | A1 |
20110015716 | Silverman | Jan 2011 | A1 |
20110022076 | Lashinski | Jan 2011 | A1 |
20110125258 | Centola | May 2011 | A1 |
20110213459 | Garrison et al. | Sep 2011 | A1 |
20110257592 | Ventura et al. | Oct 2011 | A1 |
20120010151 | Lenker et al. | Apr 2012 | A1 |
20120083877 | Nguyen et al. | Apr 2012 | A1 |
20120172781 | Wang | Jul 2012 | A1 |
20120172965 | Kratzberg et al. | Jul 2012 | A1 |
20120209375 | Madrid et al. | Aug 2012 | A1 |
20130131787 | Ginn | May 2013 | A1 |
20130138201 | Ginn | May 2013 | A1 |
20140336695 | Naor et al. | Nov 2014 | A1 |
20140336752 | Ginn et al. | Nov 2014 | A1 |
20160128723 | Ginn et al. | May 2016 | A1 |
20160338828 | Ginn | Nov 2016 | A1 |
20170014232 | Ginn et al. | Jan 2017 | A1 |
20200360140 | Ginn et al. | Nov 2020 | A1 |
Number | Date | Country |
---|---|---|
2012335016 | May 2014 | AU |
2012335016 | Jul 2017 | AU |
2855387 | May 2013 | CA |
3082091 | Jan 2023 | CA |
1204242 | Jan 1999 | CN |
104039381 | Sep 2014 | CN |
2663355 | Nov 2013 | EP |
2776114 | Sep 2014 | EP |
2776114 | Oct 2018 | EP |
3449969 | Mar 2019 | EP |
3449969 | Feb 2023 | EP |
2776114 | Sep 1999 | FR |
2776114 | Oct 2007 | FR |
H09501594 | Feb 1997 | JP |
H11501227 | Feb 1999 | JP |
H11509130 | Aug 1999 | JP |
2001517973 | Oct 2001 | JP |
2002336261 | Nov 2002 | JP |
2003131159 | May 2003 | JP |
2003309379 | Oct 2003 | JP |
2004049545 | Feb 2004 | JP |
2004533290 | Nov 2004 | JP |
2005095242 | Apr 2005 | JP |
2005173366 | Jun 2005 | JP |
2006500970 | Jan 2006 | JP |
2008512181 | Apr 2008 | JP |
2008149619 | Jul 2008 | JP |
2009529401 | Aug 2009 | JP |
2009543655 | Dec 2009 | JP |
2011517592 | Jun 2011 | JP |
2012247510 | Dec 2012 | JP |
2013034867 | Feb 2013 | JP |
2013105107 | May 2013 | JP |
2015500681 | Jan 2015 | JP |
WO-9505207 | Feb 1995 | WO |
WO-9619941 | Jul 1996 | WO |
WO-9721403 | Jun 1997 | WO |
WO-9809678 | Mar 1998 | WO |
WO-9924102 | May 1999 | WO |
WO-0191844 | Dec 2001 | WO |
WO-02056955 | Jul 2002 | WO |
WO-03090834 | Nov 2003 | WO |
WO-2005027751 | Mar 2005 | WO |
WO-2007106755 | Sep 2007 | WO |
WO-2009131612 | Oct 2009 | WO |
2010045297 | Apr 2010 | WO |
2010105195 | Sep 2010 | WO |
WO-2011096975 | Aug 2011 | WO |
WO-2013037505 | Mar 2013 | WO |
WO-2013071179 | May 2013 | WO |
Entry |
---|
“Canadian Application Serial No. 3,082,091, Office Action dated Jun. 15, 2021”, 4 pgs. |
“Canadian Application Serial No. 3,082,091, Response filed Oct. 12, 2021 to Office Action dated Jun. 15, 2021”, 15 pgs. |
“European Application Serial No. 18201608.9, Communication Pursuant to Article 94(3) EPC dated Mar. 31, 2021”, 5 pgs. |
“European Application Serial No. 18201808.9, Response filed Oct. 11, 2021 to Communication Pursuant to Article 94(3) EPC dated Mar. 31, 2021”, 50 pgs. |
“Japanese Application Serial No. 2020-038658, Notification of Reasons for Refusal dated Sep. 27, 2021”, w/ English translation, 8 pgs. |
EP Application No. 20200790.2, Extended European Search Report, dated Feb. 5, 2021, 7 pages. |
“U.S. Appl. No. 13/673,898, Advisory Action dated Jul. 31, 2017”, 3 pgs. |
“U.S. Appl. No. 13/673,898, Advisory Action dated Aug. 5, 2016”, 5 pgs. |
“U.S. Appl. No. 13/673,898, Amendment filed Feb. 25, 2020”, 8 pgs. |
“U.S. Appl. No. 13/673,898, Appeal Brief filed Jul. 19, 2017”, 19 pgs. |
“U.S. Appl. No. 13/673,898, Appeal Brief filed Aug. 9, 2017”, 2 pgs. |
“U.S. Appl. No. 13/673,898, Appeal Decision dated Dec. 27, 2019”, 26 pgs. |
“U.S. Appl. No. 13/673,898, Examiner's Answer to Appeal Brief dated Dec. 19, 2017”, 12 pgs. |
“U.S. Appl. No. 13/673,898, Final Office Action dated Apr. 20, 2017”, 20 pgs. |
“U.S. Appl. No. 13/673,898, Final Office Action dated May 25, 2016”, 10 pgs. |
“U.S. Appl. No. 13/673,898, Non Final Office Action dated Apr. 3, 2020”, 6 pgs. |
“U.S. Appl. No. 13/673,898, Non Final Office Action dated Sep. 14, 2015”, 11 pgs. |
“U.S. Appl. No. 13/673,898, Non Final Office Action dated Nov. 16, 2016”, 16 pgs. |
“U.S. Appl. No. 13/673,898, Notice of Allowance dated Sep. 18, 2020” pp. 1-8. |
“U.S. Appl. No. 13/673,898, Notice of Non-Complaint Appeal Brief dated Aug. 2, 2017”, 2 pgs. |
“U.S. Appl. No. 13/673,898, Reply Brief filed Jan. 30, 2018”, 9 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Feb. 5, 2016 to Non Final Office Action dated Sep. 14, 2015”, 8 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Jun. 2, 2017 to Final Office Action dated Apr. 20, 2017”, 6 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Jun. 14, 2016 to Final Office Action dated May 25, 2016”, 10 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Jun. 30, 2020 to Non Final Office Action dated Apr. 3, 2020”, 8 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Aug. 7, 2015 to Restriction Requirement dated Mar. 20, 2015”, 5 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Aug. 8, 2016 to Advisory Action dated Aug. 5, 2016”, 10 pgs. |
“U.S. Appl. No. 13/673,898, Response filed Dec. 22, 2016 to Non Final Office Action dated Nov. 16, 2016”, 11 pgs. |
“U.S. Appl. No. 13/673,898, Restriction Requirement dated Mar. 20, 2015”, 6 pgs. |
“U.S. Appl. No. 13/673,911, Advisory Action dated Feb. 16, 2016”, 3 pgs. |
“U.S. Appl. No. 13/673,911, Final Office Action dated Dec. 18, 2015”, 6 pgs. |
“U.S. Appl. No. 13/673,911, Non Final Office Action dated Apr. 6, 2015”, 11 pgs. |
“U.S. Appl. No. 13/673,911, Notice of Allowance dated Mar. 11, 2016”, 9 pgs. |
“U.S. Appl. No. 13/673,911, Response filed Jan. 28, 2016 to Final Office Action dated Dec. 18, 2015”, 8 pgs. |
“U.S. Appl. No. 13/673,911, Response filed Mar. 1, 2016 to Advisory Action dated Feb. 16, 2016”, 7 pgs. |
“U.S. Appl. No. 13/673,911, Response filed Sep. 8, 2015 to Non Final Office Action dated Apr. 4, 2015”, 7 pgs. |
“U.S. Appl. No. 14/274,563, 312 Amendment filed Aug. 9, 2016”, 16 pgs. |
“U.S. Appl. No. 14/274,563, 312 Amendment filed Aug. 12, 2016”, 3 pgs. |
“U.S. Appl. No. 14/274,563, Advisory Action dated Jun. 3, 2016”, 3 pgs. |
“U.S. Appl. No. 14/274,563, Final Office Action dated Mar. 28, 2016”, 19 pgs. |
“U.S. Appl. No. 14/274,563, Non Final Office Action dated Jun. 3, 2015”, 15 pgs. |
“U.S. Appl. No. 14/274,563, Non Final Office Action dated Sep. 8, 2014”, 7 pgs. |
“U.S. Appl. No. 14/274,563, Notice of Allowance dated Aug. 8, 2016”, 11 pgs. |
“U.S. Appl. No. 14/274,563, PTO Response to Rule 312 Communication dated Sep. 26, 2016”, 2 pgs. |
“U.S. Appl. No. 14/274,563, Response filed Feb. 9, 2015 to Non Final Office Action dated Sep. 8, 2014”, 13 pgs. |
“U.S. Appl. No. 14/274,563, Response filed Apr. 29, 2016 to Final Office Action dated Mar. 28, 2016”, 9 pgs. |
“U.S. Appl. No. 14/274,563, Response filed Jun. 15, 2016 to Advisory Action dated Jun. 3, 2016”, 9 pgs. |
“U.S. Appl. No. 14/274,563, Response filed Oct. 20, 2015 to Non Final Office Action dated Jun. 3, 2015”, 11 pgs. |
“U.S. Appl. No. 14/934,767, Advisory Action dated May 23, 2019”, 3 pgs. |
“U.S. Appl. No. 14/934,767, Examiner Interview Summary dated May 14, 2018”, 3 pgs. |
“U.S. Appl. No. 14/934,767, Final Office Action dated Jan. 31, 2020”, 21 pgs. |
“U.S. Appl. No. 14/934,767, Final Office Action dated Apr. 25, 2019”, 26 pgs. |
“U.S. Appl. No. 14/934,767, Non Final Office Action dated May 3, 2018”, 18 pgs. |
“U.S. Appl. No. 14/934,767, Non Final Office Action dated Aug. 20, 2019”, 17 pgs. |
“U.S. Appl. No. 14/934,767, Response filed Mar. 5, 2018 to Restriction Requirement dated Jan. 8, 2018”, 2 pgs. |
“U.S. Appl. No. 14/934,767, Response filed May 10, 2019 to Final Office Action dated Apr. 25, 2019”, 12 pgs. |
“U.S. Appl. No. 14/934,767, Response filed Jul. 24, 2018 to Non Final Office Action dated May 3, 2018”, 11 pgs. |
“U.S. Appl. No. 14/934,767, Response filed Nov. 11, 2019 to Non Final Office Action dated Aug. 20, 2019”, 11 pgs. |
“U.S. Appl. No. 14/934,767, Restriction Requirement dated Jan. 8, 2018”, 7 pgs. |
“U.S. Appl. No. 15/228,380, Final Office Action dated Feb. 21, 2020”, 10 pgs. |
“U.S. Appl. No. 15/228,380, Final Office Action dated Nov. 14, 2018”, 8 pgs. |
“U.S. Appl. No. 15/228,380, Non Final Office Action dated Apr. 20, 2018”, 7 pgs. |
“U.S. Appl. No. 15/228,380, Non Final Office Action dated Jun. 26, 2019”, 8 pgs. |
“U.S. Appl. No. 15/228,380, Notice of Allowance dated Aug. 21, 2020”, 8 pgs. |
“U.S. Appl. No. 15/228,380, Response filed Feb. 14, 2019 to Final Office Action dated Nov. 14, 2018”, 6 pgs. |
“U.S. Appl. No. 15/228,380, Response Filed May 21, 2020 to Final Office Action dated Feb. 21, 2020”, 9 pgs. |
“U.S. Appl. No. 15/228,380, Response filed Jun. 26, 2018 to Non Final Office Action dated Apr. 20, 2018”, 7 pgs. |
“U.S. Appl. No. 15/228,380, Response filed Oct. 24, 2019 to Non Final Office Action dated Jun. 26, 2019”, 7 pgs. |
“U.S. Appl. No. 15/232,318, Examiner Interview Summary dated Nov. 20, 2018”, 3 pgs. |
“U.S. Appl. No. 15/232,318, Final Office Action dated Oct. 18, 2019”, 10 pgs. |
“U.S. Appl. No. 15/232,318, Final Office Action dated Nov. 1, 2018”, 12 pgs. |
“U.S. Appl. No. 15/232,318, Non Final Office Action dated Apr. 4, 2019”, 10 pgs. |
“U.S. Appl. No. 15/232,318, Non Final Office Action dated Apr. 6, 2018”, 13 pgs. |
“U.S. Appl. No. 15/232,318, Notice of Allowance dated Feb. 18, 2020”, 7 pgs. |
“U.S. Appl. No. 15/232,318, Preliminary Amendment filed Aug. 12, 2016”, 3 pgs. |
“U.S. Appl. No. 15/232,318, Response filed Jan. 20, 2020 to Final Office Action dated Oct. 18, 2019”, 8 pgs. |
“U.S. Appl. No. 15/232,318, Response filed Feb. 1, 2019 to Final Office Action dated Nov. 1, 2018”, 10 pgs. |
“U.S. Appl. No. 15/232,318, Response filed Jun. 19, 2018 to Non Final Office Action dated Apr. 6, 2018”, 9 pgs. |
“U.S. Appl. No. 15/232,318, Response filed Jul. 5, 2019 to Non Final Office Action dated Apr. 4, 2019”, 10 pgs. |
“Australian Application Serial No. 2012335016, First Examiner Report dated Jul. 17, 2016”, 3 pgs. |
“Australian Application Serial No. 2012335016, Response filed Jan. 12, 2017 to First Examiner Report dated Jul. 17, 2016”, 17 pgs. |
“Australian Application Serial No. 2012335016, Response filed Apr. 12, 2017 to Second Examiner Report dated Feb. 20, 2017”, 8 pgs. |
“Australian Application Serial No. 2012335016, Response filed Jun. 29, 2017 to Third Examiner Report dated Jun. 12, 2017”, 11 pgs. |
“Australian Application Serial No. 2012335016, Second Examiner Report dated Feb. 20, 2017”, 3 pgs. |
“Australian Application Serial No. 2012335016, Third Examiner Report dated Jun. 12, 2017”, 4 pgs. |
“Canadian Application Serial No. 2,855,387, Office Action dated Jun. 12, 2018”, 4 pgs. |
“Canadian Application Serial No. 2,855,387, Office Action dated Mar. 8, 2019”, 4 pgs. |
“Canadian Application Serial No. 2,855,387, Response filed Sep. 6, 2019 to Office Action dated Mar. 8, 2019”, 78 pgs. |
“Canadian Application Serial No. 2,855,387, Response filed Dec. 12, 2018 to Office Action dated Jun. 12, 2018”, 27 pgs. |
“Canadian Application Serial No. 2,855,387, Voluntary Amendment filed Oct. 29, 2019”, 14 pgs. |
“Canadian Application Serial No. 3,082,091, Voluntary Amendment Filed Oct. 21, 2020”, 15 pgs. |
“Chinese Application Serial No. 201280066517.X, Office Action dated Oct. 26, 2015”, with English translation of claims, 17 pgs. |
“European Application Serial No. 12847961.5, Communication Pursuant to Article 94(3) EPC dated Mar. 29, 2016”, 5 pgs. |
“European Application Serial No. 12847961.5, Communication Pursuant to Article 94(3) EPC dated Aug. 17, 2017”, 6 pgs. |
“European Application Serial No. 12847961.5, Communication Pursuant to Article 94(3) EPC dated Nov. 15, 2016”, 5 pgs. |
“European Application Serial No. 12847961.5, Extended European Search Report dated May 22, 2015”, 8 pgs. |
“European Application Serial No. 12847961.5, Intention to Grant mailed Apr. 26, 2018”, 95 pgs. |
“European Application Serial No. 12847961.5, Intention to Grant mailed Sep. 17, 2018”, 95 pgs. |
“European Application Serial No. 12847961.5, Response filed Jan. 2, 2015 to Communication Pursuant to Rules 161(1) and 162 EPC dated Jun. 23, 2014”, 11 pgs. |
“European Application Serial No. 12847961.5, Response filed May 24, 2017 to Communication Pursuant to Article 94(3) EPC dated Nov. 15, 2016”, 52 pgs. |
“European Application Serial No. 12847961.5, Response filed Sep. 5, 2018 to Intention to Grant mailed Apr. 26, 2018”, 8 pgs. |
“European Application Serial No. 12847961.5, Response filed Oct. 10, 2016 to Communication Pursuant to Article 94(3) EPC dated Mar. 29, 2016”, 13 pgs. |
“European Application Serial No. 12847961.5, Response filed Dec. 21, 2015 to Extended European Search Report dated May 22, 2015”, 12 pgs. |
“European Application Serial No. 12847961.5, Response filed Dec. 29, 2017 to Communication Pursuant to Article 94(3) EPC dated Aug. 17, 2017”, 52 pgs. |
“European Application Serial No. 14797200.4, Extended European Search Report dated Nov. 7, 2016”, 8 pgs. |
“European Application Serial No. 14797200.4, Response filed Jun. 6, 2017 to Extended European Search Report dated Nov. 7, 2016”, 21 pgs. |
“European Application Serial No. 18201608.9, Extended European Search Report dated Feb. 1, 2019”, 10 pgs. |
“International Application Serial No. PCT/US2012/064540, International Preliminary Report on Patentability dated May 22, 2014”, 11 pgs. |
“International Application Serial No. PCT/US2012/064540, International Search Report dated Feb. 6, 2013”, 2 pgs. |
“International Application Serial No. PCT/US2012/064540, Written Opinion dated Feb. 6, 2013”, 9 pgs. |
“International Application Serial No. PCT/US2014/037580, International Preliminary Report on Patentability dated Nov. 19, 2015”, 8 pgs. |
“International Application Serial No. PCT/US2014/037924, International Search Report dated Oct. 17, 2014”, 2 pgs. |
“Israel Application Serial No. 232542, Office Action dated Sep. 4, 2018”, with Concise Statement of Relevance, 5 pgs. |
“Israel Application Serial No. 232542, Office Action dated Sep. 18, 2017”, with Concise Statement of Relevance, 3 pgs. |
“Israel Application Serial No. 232542, Response filed Jan. 18, 2018 to Office Action dated Sep. 18, 2017”, with Concise Statement of Relevance, 2 pgs. |
“Israel Application Serial No. 232542, Response filed Dec. 16, 2018 to Office Action dated Sep. 4, 2018”, with Concise Statement of Relevance, 2 pgs. |
“Israel Application Serial No. 242506, Office Action dated May 27, 2019”, with English translation, 7 pgs. |
“Japanese Application Serial No. 2014-541354, Notice of Reason for Rejection dated Jul. 28, 2016”, w/ English Translation, 22 pgs. |
“Japanese Application Serial No. 2017-005031, Notice of Reasons for Rejection dated Oct. 23, 2017”, with English translation of claims, 37 pgs. |
“Japanese Application Serial No. 2017-005031, Office Action dated Jan. 25, 2018”, with English translation of claims, 5 pgs. |
“U.S. Appl. No. 16/884,760, Final Office Action dated Feb. 16, 2023”, 10 pgs. |
“U.S. Appl. No. 16/884,760, Non Final Office Action dated Jun. 23, 2022”, 4 pgs. |
“U.S. Appl. No. 16/884,760, Response filed Oct. 21, 22 to Non Final Office Action dated Jun. 23, 2022”, 9 pgs. |
“Canadian Application Serial No. 3,082,091, Office Action dated Dec. 3, 2021”, 3 pgs. |
“Canadian Application Serial No. 3,082,091, Response filed Mar. 16, 2022 to Office Action dated Dec. 3, 2021”, 7 pgs. |
“U.S. Appl. No. 16/884,760, Advisory Action dated Jun. 27, 2023”, 3 pgs. |
“U.S. Appl. No. 16/884,760, Response filed May 16, 23 to Final Office Action dated Feb. 16, 2023”, 11 pgs. |
“European Application Serial No. 23153606.1, Extended European Search Report dated Apr. 19, 2023”, 9 pgs. |
Number | Date | Country | |
---|---|---|---|
20210068953 A1 | Mar 2021 | US |
Number | Date | Country | |
---|---|---|---|
61717575 | Oct 2012 | US | |
61558397 | Nov 2011 | US | |
61558357 | Nov 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15228380 | Aug 2016 | US |
Child | 17100724 | US | |
Parent | 13673898 | Nov 2012 | US |
Child | 15228380 | US |